Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.140
-0.090 (-7.32%)
At close: Apr 1, 2025, 4:00 PM
1.274
+0.134 (11.74%)
After-hours: Apr 1, 2025, 4:38 PM EDT
Marker Therapeutics Revenue
In the year 2024, Marker Therapeutics had annual revenue of $6.59M with 99.06% growth. Marker Therapeutics had revenue of $2.25M in the quarter ending December 31, 2024, with 113.13% growth.
Revenue (ttm)
$6.59M
Revenue Growth
+99.06%
P/S Ratio
1.68
Revenue / Employee
$823,885
Employees
8
Market Cap
12.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.59M | 3.28M | 99.06% |
| Dec 31, 2023 | 3.31M | -202.41K | -5.76% |
| Dec 31, 2022 | 3.51M | 2.27M | 182.96% |
| Dec 31, 2021 | 1.24M | 774.93K | 166.01% |
| Dec 31, 2020 | 466.79K | 253.59K | 118.95% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
MRKR News
- 8 hours ago - Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference - GlobeNewsWire
- 1 day ago - Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results - GlobeNewsWire
- 5 weeks ago - Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 3 months ago - Marker Therapeutics Announces $16.1 Million Private Placement - GlobeNewsWire
- 3 months ago - Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma - GlobeNewsWire
- 3 months ago - Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer - GlobeNewsWire
- 4 months ago - Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium - GlobeNewsWire
- 4 months ago - Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit - GlobeNewsWire